Restricted accessResearch articleFirst published online 2020-04
Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics
Lung adenocarcinoma (LUAD) accounts for an increasing proportion of non–small-cell lung cancer and an increasing number of cancer-related deaths worldwide. However, few biomarkers are available for prognosis and patient stratification. In all eight datasets from the Oncomine and The Cancer Genome Atlas (TCGA) LUAD cohorts, solute carrier family 2 member 1 (SLC2A1) was significantly more highly expressed in LUAD tissue than in normal lung tissue. High SLC2A1 expression was also significantly (p < 0.05) associated with a poor prognosis in stage I, II, and III subgroups using the Kaplan–Meier plotter. In the National Cancer Center of China (NCC) cohort, SLC2A1 expression correlated significantly (p < 0.05) with several parameters, including sex, smoking history, tumor size, tumor differentiation, T stage, N stage, and pathologic TNM stage. Moreover, multivariate Cox regression indicated SLC2A1 to be an independent prognostic factor (p < 0.05) in both TCGA and NCC cohorts. Eleven hallmark pathways were significantly enriched (p < 0.01, false discovery rate <0.25) in the high-SLC2A1 expression group. SLC2A1 is a promising biomarker that can be used to predict the prognosis of LUAD.
Get full access to this article
View all access options for this article.
References
1.
AshburnerM., BallC.A., BlakeJ.A., BotsteinD., ButlerH., CherryJ.M., et al. (2000). Gene ontology: tool for the unification of biology. Nat Genet, 25, 25.
2.
Barr KumarakulasingheN., ZanwijkN.V., and SooR.A. (2015). Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology, 20, 370–378.
3.
BolG.M., VesunaF., XieM., ZengJ., AzizK., GandhiN., et al. (2015). Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med, 7, 648–669.
4.
BoroughsL.K., and DeBerardinisR.J. (2015). Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol, 17, 351–359.
5.
ChenW., ZhengR., BaadeP.D., ZhangS., ZengH., BrayF., et al. (2016). Cancer statistics in China, 2015. CA Cancer J Clin, 66, 115–132.
6.
DeBerardinisR.J., LumJ.J., HatzivassiliouG., and ThompsonC.B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 7, 11–20.
7.
DoS.K., JeongJ.Y., LeeS.Y., ChoiJ.E., HongM.J., KangH.-G., et al. (2018). Glucose transporter 1 gene variants predict the prognosis of patients with early-stage non-small cell lung cancer. Ann Surg Oncol, 25, 3396–3403.
8.
FranceschiniA., SzklarczykD., FrankildS., KuhnM., SimonovicM., RothA., et al. (2012). STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res, 41, D808–D815.
9.
GaoL.-W., and WangG.-L. (2018). Comprehensive bioinformatics analysis identifies several potential diagnostic markers and potential roles of cyclin family members in lung adenocarcinoma. Onco Targets Ther, 11, 7407.
10.
GriffinJ.L., and ShockcorJ.P. (2004). Metabolic profiles of cancer cells. Nat Rev Cancer, 4, 551.
11.
GyőrffyB., SurowiakP., BudcziesJ., and LánczkyA. (2013). Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One, 8, e82241.
12.
KalemkerianG.P., NarulaN., KennedyE.B., BiermannW.A., DoningtonJ., LeighlN.B., et al. (2018). Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol, 36, 911–919.
13.
KanehisaM. (2002). The KEGG database. In Novartis Foundation Symposium. Chichester: John Wiley, pp. 91–100.
LiaoB.-C., LinC.-C., and YangJ.C.-H. (2015). Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol, 27, 94–101.
16.
LiaoY., YinG., WangX., ZhongP., FanX., and HuangC. (2019). Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis. Oncol Lett, 18, 3723–3733.
17.
LibertiM.V., and LocasaleJ.W. (2016). The Warburg effect: how does it benefit cancer cells?. Trends Biochem Sci, 41, 211–218.
18.
LindemanN.I., CagleP.T., AisnerD.L., ArcilaM.E., BeasleyM.B., BernickerE.H., et al. (2018). Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol, 13, 323–358.
19.
Lopez-SerraP., MarcillaM., VillanuevaA., Ramos-FernandezA., PalauA., LealL., et al. (2014). A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nat Commun, 5, 3608.
20.
MaoY., YangD., HeJ., and KrasnaM.J. (2016). Epidemiology of lung cancer. Surg Oncol Clin, 25, 439–445.
21.
MokT.S., WuY.-L., AhnM.-J., GarassinoM.C., KimH.R., RamalingamS.S., et al. (2017). Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med, 376, 629–640.
22.
OoiA.T., and GompertsB.N. (2015). Molecular pathways: targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA. Clin Cancer Res, 21, 2440–2444.
23.
PostowM.A., CallahanM.K., and WolchokJ.D. (2015). Immune checkpoint blockade in cancer therapy. J Clin Oncol, 33, 1974.
24.
RhodesD.R., YuJ., ShankerK., DeshpandeN., VaramballyR., GhoshD., et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6, 1–6.
25.
RizviH., Sanchez-VegaF., LaK., ChatilaW., JonssonP., HalpennyD., et al. (2018). Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol, 36, 633.
26.
ShiJ., ZhangY., QinB., WangY., and ZhuX. (2019). Long non-coding RNA LINC00174 promotes glycolysis and tumor progression by regulating miR-152-3p/SLC2A1 axis in glioma. J Exp Clin Cancer Res, 38, 1–12.
27.
SoriaJ.-C., OheY., VansteenkisteJ., ReungwetwattanaT., ChewaskulyongB., LeeK.H., et al. (2018). Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med, 378, 113–125.
28.
StarkR., GrzelakM., and HadfieldJ. (2019). RNA sequencing: the teenage years. Nat Rev Genet, 20, 631–656.
29.
SteuerC.E., KhuriF.R., and RamalingamS.S. (2015). The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer, 121, E1–E6.
30.
SubramanianA., TamayoP., MoothaV.K., MukherjeeS., EbertB.L., GilletteM.A., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102, 15545–15550.
31.
TangZ., LiC., KangB., GaoG., LiC., and ZhangZ. (2017). GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 45, W98–W102.
32.
TorreL.A., BrayF., SiegelR.L., FerlayJ., Lortet-TieulentJ., and JemalA. (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87–108.
33.
WangY., ShiS., DingY., WangZ., LiuS., YangJ., et al. (2017). Metabolic reprogramming induced by inhibition of SLC2A1 suppresses tumor progression in lung adenocarcinoma. Int J Clin Exp Pathol, 10, 10759–10769.
34.
YanS., WangY., ChenM., LiG., and FanJ. (2015). Deregulated SLC2A1 promotes tumor cell proliferation and metastasis in gastric cancer. Int J Mol Sci, 16, 16144–16157.
35.
YangJ., WenJ., TianT., LuZ., WangY., WangZ., et al. (2017). GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget, 8, 11788.
36.
YuanX., WuH., XuH., XiongH., ChuQ., YuS., et al. (2015). Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett, 369, 20–27.
37.
ZhangB., XieZ., and LiB. (2018). The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: a meta-analysis. Gene, 689, 76–83.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
